Chih-Hsin Yang - JoVE Visualize

Showing results (171-180 of 324) with videos related to

Pageof 33

Sort By:

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.

Cancers|January 16, 2021

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer CellsChia-Chi Hsu, Albert Ying-Po Yang, Jui-Yi Chen, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancerBruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerKang-Yi Su, Hsuan-Yu Chen, Ker-Chau Li, et al.

Clinical Lung Cancer|December 3, 2014

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaBin-Chi Liao, Yu-Yun Shao, Ho-Min Chen, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populationsYen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, et al.

Cancer Letters|September 1, 2012

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitorsCheng-Po Huang, Meng-Feng Tsai, Tzu-Hua Chang, et al.

Lung Cancer (Amsterdam, Netherlands)|July 28, 2021

Real-world insights into patients with advanced NSCLC and MET alterationsMarisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010

Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsChia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, et al.

Pageof 33

Showing results (171-180 of 324) with videos related to

Sort By:

Pageof 33

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.

Cancers|January 16, 2021

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer CellsChia-Chi Hsu, Albert Ying-Po Yang, Jui-Yi Chen, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancerBruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerKang-Yi Su, Hsuan-Yu Chen, Ker-Chau Li, et al.

Clinical Lung Cancer|December 3, 2014

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaBin-Chi Liao, Yu-Yun Shao, Ho-Min Chen, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populationsYen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, et al.

Cancer Letters|September 1, 2012

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitorsCheng-Po Huang, Meng-Feng Tsai, Tzu-Hua Chang, et al.

Lung Cancer (Amsterdam, Netherlands)|July 28, 2021

Real-world insights into patients with advanced NSCLC and MET alterationsMarisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010

Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsChia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, et al.

Pageof 33